Ammonia‐lowering strategies for the treatment of hepatic encephalopathy
dc.contributor.author | Rose, Christopher | |
dc.date.accessioned | 2020-11-12T13:04:38Z | |
dc.date.available | NO_RESTRICTION | fr |
dc.date.available | 2020-11-12T13:04:38Z | |
dc.date.issued | 2012-08-08 | |
dc.identifier.uri | http://hdl.handle.net/1866/24043 | |
dc.publisher | Wiley | fr |
dc.subject | Brain | fr |
dc.subject | Hepatic | fr |
dc.subject | Metabolism | fr |
dc.subject | Neurological | fr |
dc.subject | Therapeutics | fr |
dc.title | Ammonia‐lowering strategies for the treatment of hepatic encephalopathy | fr |
dc.type | Article | fr |
dc.contributor.affiliation | Université de Montréal. Faculté de médecine. Département de médecine | fr |
dc.identifier.doi | 10.1038/clpt.2012.112 | |
dcterms.abstract | Hyperammonemia leads to neurotoxic levels of brain ammonia and is a major factor involved in the pathogenesis of hepatic encephalopathy (HE). Ammonia‐lowering treatments primarily involve two strategies: inhibiting ammonia production and/or increasing ammonia removal. Targeting the gut has been the primary focus for many years, with the goal of inhibiting the generation of ammonia. However, in the context of liver failure, extrahepatic organs containing ammonia metabolic pathways have become new potential ammonia‐lowering targets. Skeletal muscle has the capacity to remove ammonia by producing glutamine through the enzyme glutamine synthetase (amidation of glutamate) and, given its large mass, has the potential to be an important ammonia‐removing organ. On the other hand, glutamine can be deaminated to glutamate by phosphate‐activated glutaminase, thus releasing ammonia (ammonia rebound). Therefore, new treatment strategies are being focused on stimulating the removal of both ammonia and glutamine. | fr |
dcterms.isPartOf | urn:ISSN:0009-9236 | fr |
dcterms.isPartOf | urn:ISSN:1532-6535 | fr |
dcterms.language | eng | fr |
UdeM.ReferenceFournieParDeposant | 10.1038/clpt.2012.112 | fr |
UdeM.VersionRioxx | Version acceptée / Accepted Manuscript | fr |
oaire.citationTitle | Clinical pharmacology and therapeutics | fr |
oaire.citationVolume | 92 | fr |
oaire.citationIssue | 3 | fr |
oaire.citationStartPage | 321 | fr |
oaire.citationEndPage | 331 | fr |
Files in this item
This item appears in the following Collection(s)
This document disseminated on Papyrus is the exclusive property of the copyright holders and is protected by the Copyright Act (R.S.C. 1985, c. C-42). It may be used for fair dealing and non-commercial purposes, for private study or research, criticism and review as provided by law. For any other use, written authorization from the copyright holders is required.